Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment.
Business
The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
Related
Business
Arthur Hayes sold ENA 98% below his profit target
Arthur Hayes wrote in August 2025 that ENA “can 51x from the current levels.” Saturday, he said he dumped it 98% below his profit target. The post Arthur Hayes sold ENA 98% below his profit target appeared first on Protos.
Business
Two stock picks to capitalize on Wall Street’s misguided AI fears
Sowmdeb Sen of Silvant Capital Management highlights companies poised to benefit from the acceleration of AI spending.
Business
Anthropic Files for IPO as Crypto Traders Price It Near $1.9T
Anthropic filed for a Wall Street debut on Monday, while crypto traders priced the artificial intelligence giant near $1.87 trillion. Prediction markets went further, putting substantial odds on a $2 trillion valuation before its first tra…
Business
Base Promotes 'Tokenized Anthropic Shares' as Trade.xyz Opens Pre-IPO Bets
Trade.xyz's new ANT contract offers up to 10x leverage without equity ownership, while Base's pitch identifies no issuer or token contract.